Ultragenyx is selling it's Rare Pediatric Disease Priority Review Voucher earned for Genglycos’s approval for $210 million.
Feature|Articles|August 25, 2026
Why Integrated GMP Operating Models Are Reshaping Outsourced Manufacturing
Author(s)Adam Bartley
Cleanroom hosting with integrated GMP operating models is giving emerging biopharma companies a new middle path between building and full outsourcing.
Advertisement
Advertisement
For decades, biopharma companies evaluating outsourced manufacturing faced a binary choice. They could lease facility space and build the surrounding operations themselves, or they could outsource the entire effort to a contract development and manufacturing organization (CDMO). Both options worked, but neither was particularly well-suited to the realities of how emerging biopharma companies actually develop and manufacture today.
Related to this article
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Tukysa adds a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer; liver toxicity monitoring remains a key consideration.
What North American and APAC sponsors need to know about EU Joint Clinical Assessment — and why EMA approval doesn't guarantee reimbursement.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
FDA Approves Expanded Indication for Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy
FDA has expanded Camzyos's approval to treat symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients as young as 12.
MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews
MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Advertisement
Advertisement